MARKET

MNMD

MNMD

Mind Medicine
NASDAQ
12.35
-0.08
-0.64%
After Hours: 12.25 -0.1 -0.81% 19:59 12/05 EST
OPEN
12.46
PREV CLOSE
12.43
HIGH
12.68
LOW
12.01
VOLUME
1.41M
TURNOVER
--
52 WEEK HIGH
14.43
52 WEEK LOW
4.700
MARKET CAP
1.22B
P/E (TTM)
-6.2630
1D
5D
1M
3M
1Y
5Y
1D
MindMed Grants Stock Options to New Employees
Reuters · 5d ago
Weekly Report: what happened at MNMD last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at MNMD last week (1117-1121)?
Weekly Report · 11/24 10:06
Will Larger-Than-Expected Losses Alter Mind Medicine (MNMD)'s Investment Narrative?
Simply Wall St · 11/18 23:27
Weekly Report: what happened at MNMD last week (1110-1114)?
Weekly Report · 11/17 10:06
Psychedelic: Atai Beckley, Cybin report quarterly earnings
TipRanks · 11/13 16:31
MindMed’s Earnings Call: Positive Outlook Amid Financial Challenges
TipRanks · 11/12 00:20
Mind Medicine’s Strong Financial Position and Clinical Progress Drive Buy Rating
TipRanks · 11/11 20:35
More
About MNMD
Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Webull offers Mind Medicine (MindMed) Inc stock information, including NASDAQ: MNMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNMD stock methods without spending real money on the virtual paper trading platform.